Novoste to seek FDA approval of beta radiation therapy for in-stent restenosis following successful START trial
This article was originally published in Clinica
Executive Summary
Novoste looks set to submit its intravascular beta radiation therapy for treating in-stent restenosis to the FDA for US marketing approval during the next few months, following positive results from a pivotal 50-centre trial of the treatment.